Humana to divest Gentiva stake in $900 million deal
Humana Inc. agreed to sell its minority stake in Gentiva to a consortium for $900 million. The deal closes in Q3 2026 pending regulatory approvals.
*this image is generated using AI for illustrative purposes only.
Humana Inc. has entered into a definitive agreement to divest its minority interest in Gentiva, a provider of end-of-life services, for approximately $900 million. The sale involves a consortium of investors acquiring all or substantially all of Humana's stake in the entity, which operates as the nation's largest provider of hospice and palliative care. Humana intends to use the net proceeds from the transaction for general corporate purposes. The deal is projected to close in the third quarter of 2026, pending regulatory approvals and other customary closing conditions.
The company stated that it does not expect the transaction to have a material impact on its 2026 earnings. Humana's ownership in Gentiva originated from its 2021 acquisition of the remaining interest in Kindred at Home. Following that acquisition, Humana had signaled its intention to divest non-core businesses within the Kindred at Home portfolio, specifically hospice, palliative, and personal health care services.
In 2022, Humana agreed to sell a majority interest in the Hospice and Personal Care divisions of its Kindred at Home subsidiary to Clayton, Dubilier & Rice (CD&R). These divisions were subsequently restructured into a standalone business and rebranded as Gentiva. The company currently provides services through more than 430 locations across 35 states, supported by a network of clinicians and caregivers.
Guggenheim Securities, LLC is acting as financial advisor to Humana. Fried, Frank, Harris, Shriver & Jacobson LLP and Manatt, Phelps & Phillips LLP are acting as legal advisors to Humana.
Transaction Details
| Aspect | Details |
|---|---|
| Transaction Value | ~$900 million |
| Buyer | Consortium of investors |
| Asset | Minority interest in Gentiva |
| Expected Close | Q3 2026 |
| Use of Proceeds | General corporate purposes |
How does Humana plan to allocate the $900 million in net proceeds to drive growth in its core insurance segments?
What strategic rationale drove the decision to delay the transaction closing until the third quarter of 2026?
Could this divestment signal a broader trend of payors exiting the direct provision of end-of-life care services?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
